Yousif Capital Management LLC Has $1.09 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Yousif Capital Management LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,902 shares of the medical research company’s stock after selling 181 shares during the period. Yousif Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,090,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Mizuho Securities USA LLC lifted its position in Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after acquiring an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd lifted its position in Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after acquiring an additional 90,000 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $152.07 on Friday. The stock has a market cap of $7.78 billion, a P/E ratio of 19.03, a PEG ratio of 6.47 and a beta of 1.37. The company’s 50-day simple moving average is $176.43 and its 200 day simple moving average is $191.11. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. TD Cowen boosted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).